1Pantoflikova D,Dorta G,Jornod P,et al.Identification of the characteristics influencing the degree of antisecretory activity of PPIs.Gastroenterology,2000,118:A1290.
2Stedman CA,Barclay ML.Comparison of the pharma cokinetics,acid suppression and efficacy of proton pump inhibitors.Aliment Pharmacol Ther,2000,14:963-978.
3Hawkey CJ,Atherton JC,Treichel HC,et al.Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease.Aliment Pharmacol Ther,2003,17:1065-
4Wong BC,Wong WM,Yee YK,et al.Rabeprazole-based 3-day and 7-day triple therapy vs.omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection.Aliment Pharmacol Ther,2001,15:1959-1965.
1Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus on the management of Helicobacterpylori infection. J Gastroenterol Hepatol, 1998,13: 1～12.
2European Helicobacter pylori Study Group. Current European concepts in the management ofHelicobacter pylori infection. The Maastricht Consensus Report. Gut, 1997, 41: 8～13.
3Miwa H, Ohkura R, Murai T, Sato K, NagaharaA, Hirai S, Watanabe S, Sato N. Impact of Rabeprazole, a new proton pump inhibitor, in tripletherapy of Helicobacter pylori infection-comparison with omeprazole and lansoprazole. AlimentPharmacol Ther, 1999, 13: 741～746.
4Lind T, Veldhuyzen van Zanten S, Unge P, SpillerR, Bayerdorffer E, O'Morain C, Bardhan KD, Bradette M, Chiba N, Wrangstadh M, Cederberg C,Idstrom JP. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study.Helicobacter, 1996, 1: 138～144.
5Besancon M, Simon A, Sachs G, Shin JM. Sites ofreaction of the gastric H, K-ATPase with extracytoplasmic thiol reagents. J Biol Chem, 1997,272: 22438～22446.
6Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Comparison[correction of Double-blind, Placebo-Controlledcomparison] of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active gastric ulcer- a European multicentre study. The European Rabeprazole Study Group. Aliment Pharmacol Ther,1998, 12: 789～795.
7Hongo M, Kimpara T, Moriyama S, Ohara S, SoneS, Tamura T, Asaki S, Toyota T. Effect of rabeprazole (E3810), a novel proton pump inhib- itor, oningastric pH in healthy volunteers. Tohodu J ExpMed, 1998, 186: 43～50.
9Thjodleifsson B, Beker JA, Dekkers C, Bjaaland T,Finnegan V, Humphries TJ. Rabeprazole versusomeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a doubleblind, multicenter, European trial. The EuropeanRabeprazole Study Group. Dig Dis Sci, 2000, 45:845 ～853.
10Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in thetreatment of active duodenal ulcer: a Europeanmulticentre study. Aliment Pharmacol Ther, 1999,13: 179～186.
